Switzerland · Delayed Price · Currency is CHF Cosmo Company Description
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss.
It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system.
The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026.
The company was founded in 1997 and is headquartered in Dublin, Ireland.
| Country | Netherlands |
| Founded | 1997 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 325 |
| CEO | Giovanni Di Napoli |
Contact Details
Address: Riverside 2 Dublin, D02 KV60 Ireland | |
| Phone | 353 1 817 0370 |
| Website | cosmopharma.com |
Stock Details
| Ticker Symbol | COPN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | NL0011832936 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Giovanni Di Napoli | Chief Executive Officer and Director |
| Alessandro E. Della Cha LL.M | Non Executive Chairman |
| Mauro Severino Ajani | Founder and Non-Executive Director |
| Niall Donnelly | Executive Vice President of Corporate Governance, Chief Sustainability Officer and Executive Director |
| Svetlana Sigalova | Chief Financial Officer |
| Davide Malavasi | Qualified Person and Technical Director |
| Luigi Longo | Chief Scientific Officer |
| Federico Sommariva | Chief Legal Counsel |
| Silvia Miliani | Chief Human Resources Officer |
| Ngo Dinh Nhan | President of Cosmo Intelligent Medical Devices |